WallStSmart

RLX Technology Inc (RLX)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 49% more annual revenue ($5.40B vs $3.62B). RMD leads profitability with a 27.5% profit margin vs 25.5%. RLX trades at a lower P/E of 21.6x. RMD earns a higher WallStSmart Score of 70/100 (B).

RLX

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.0Value: 8.3Quality: 7.8
Piotroski: 5/9

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RLXUndervalued (+47.9%)

Margin of Safety

+47.9%

Fair Value

$4.68

Current Price

$2.21

$2.47 discount

UndervaluedFair: $4.68Overvalued
RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RLX5 strengths · Avg: 9.8/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
46.8%10/10

Revenue surging 46.8% year-over-year

EPS GrowthGrowth
81.9%10/10

Earnings expanding 81.9% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Profit MarginProfitability
25.5%9/10

Keeps 26 of every $100 in revenue as profit

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

RLX1 concerns · Avg: 3.0/10
Return on EquityProfitability
5.9%3/10

ROE of 5.9% — below average capital efficiency

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : RLX

The strongest argument for RLX centers on Price/Book, Revenue Growth, EPS Growth. Profitability is solid with margins at 25.5% and operating margin at 11.0%. Revenue growth of 46.8% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : RLX

The primary concerns for RLX are Return on Equity.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

RLX profiles as a growth stock while RMD is a mature play — different risk/reward profiles.

RLX carries more volatility with a beta of 1.23 — expect wider price swings.

RLX is growing revenue faster at 46.8% — sustainability is the question.

RLX generates stronger free cash flow (358M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 68/100), backed by strong 27.5% margins and 11.0% revenue growth. RLX offers better value entry with a 47.9% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

RLX Technology Inc

CONSUMER DEFENSIVE · TOBACCO · China

RLX Technology Inc., researches, develops, manufactures, distributes and sells e-vapor products in the People's Republic of China. The company is headquartered in Beijing, China.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?